

## Accepted Manuscript

Extensive testing or focused testing of Patients with Elevated Liver Enzymes

Elliot B. Tapper, Sameer D. Saini, Neil Sengupta

PII: S0168-8278(16)30544-X

DOI: <http://dx.doi.org/10.1016/j.jhep.2016.09.017>

Reference: JHEPAT 6273

To appear in: *Journal of Hepatology*


Received Date: 21 June 2016

Revised Date: 30 August 2016

Accepted Date: 1 September 2016

Please cite this article as: Tapper, E.B., Saini, S.D., Sengupta, N., Extensive testing or focused testing of Patients with Elevated Liver Enzymes, *Journal of Hepatology* (2016), doi: <http://dx.doi.org/10.1016/j.jhep.2016.09.017>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Extensive testing or focused testing of Patients with Elevated Liver Enzymes

Short title: Elevated Liver Enzymes

Elliot B. Tapper MD, (1) Sameer D. Saini MD, (2) Neil Sengupta MD, (3)

1. Elliot B. Tapper MD, [etapper@umich.edu](mailto:etapper@umich.edu); Division of Gastroenterology, University of Michigan, Ann Arbor
2. Sameer D. Saini MD, [sdsaini@med.umich.edu](mailto:sdsaini@med.umich.edu); Division of Gastroenterology, University of Michigan, Ann Arbor
3. Neil Sengupta MD. [nsengupta@medicine.bsd.uchicago.edu](mailto:nsengupta@medicine.bsd.uchicago.edu). Division of Gastroenterology/Hepatology/Nutrition, Department of Medicine, University of Chicago, Chicago

**Reprints and correspondence:**

Elliot B. Tapper, MD  
3912 Taubman  
1500 E Medical Center Dr  
Ann Arbor, MI 48109  
(734) 647-9252 office  
(734) 936-7392 fax  
[etapper@umich.edu](mailto:etapper@umich.edu)

---

word count: 3454, Figures: 1, Tables 4.

**Financial support and disclosure:** Neither author has financial support to disclose in relation to this study. Neither author has a conflict of interest to report.

**Disclosure:** None of the authors reports financial support for this study or conflicts of interest.

**Roles:** Elliot Tapper is the guarantor of this article. Concept (Tapper), Analysis (Tapper, Sengupta, Saini), Writing (Tapper), Critical revision (Sengupta, Saini)

**Keywords:** cost-effectiveness, liver disease, alcohol, hepatitis c, NAFLD

**Abbreviations:** NALFD = Nonalcoholic Fatty Liver Disease, ALD = Alcoholic liver disease, HBV = Hepatitis B, HCV = Hepatitis C, PBC = Primary Biliary Cholangitis, PSC = Primary Sclerosing Cholangitis, AIH = autoimmune hepatitis, WD = Wilson Disease, AATD = Alpha-1 Antitrypsin Deficiency, DILI = drug-induced liver injury, US = United States, ALT = Alanine aminotransferase, PCR = polymerase chain reactions, NHANES III = National Health and

Download English Version:

<https://daneshyari.com/en/article/5660348>

Download Persian Version:

<https://daneshyari.com/article/5660348>

[Daneshyari.com](https://daneshyari.com)